Search

Your search keyword '"Pascual, Lauren"' showing total 22 results
Start Over Author "Pascual, Lauren"
22 results on '"Pascual, Lauren"'

1. Ancestral Diversity in Pharmacogenomics Affects Treatment for Hispanic/Latine Populations With Inflammatory Bowel Disease

Author

Ioannou, Stephanie, Beecham, Ashley, Gomez, Lissette, Dauer, Ryan, Khakoo, Nidah, Pascual, Lauren, Quintero, Maria, Lopez, Joanna, Leavitt, James S., Solis, Norma, Ortega, Mailenys, Deshpande, Amar R., Kerman, David H., Proksell, Siobhan, Torres, Esther A., Haritunians, Talin, Li, Dalin, Abreu, Maria T., McGovern, Dermott P.B., McCauley, Jacob L., and Damas, Oriana M.

Published
2024
Full Text
View/download PDF

3. Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy.

Author

Danish, Adnan, Pia, Alexandra Della, Fogel, Lindsay, Alkhatatneh, Hassan, Zhao, Charles, Varughese, Tony, Al Feghali, Karine A., Pascual, Lauren, Sinclaire, Brittany, Marafelias, Michael, Zenreich, Joshua, Yen-Hong Kuo, Feldman, Tatyana A., Yi Zhang, Goy, Andre H., Ip, Andrew, and Rowley, Scott D.

Subjects
NON-Hodgkin's lymphoma, HOCKEY, CD19 antigen, RADIOTHERAPY, T cells
Abstract

Background and purpose: The aim of this study was to determine the prevalence of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) meeting high-risk criteria for early relapse after CD19 CAR T-cell therapy (CART) who have disease encompassable in a standard radiation therapy (RT) plan (defined as <5 malignant lesions) and may benefit from bridging RT prior to CD19 CART. Materials and methods: This is a single-center, retrospective study of patients with R/R NHL who received CD19 CART from 2018 to 2022. Eligible patients had pre-apheresis radiologic studies available. All patients were classified by number of lesions and history of high-risk disease criteria: bulky disease ≥10 cm, ≥1 extranodal (EN) sites, LDH ≥normal, or ≥1 lesion with SUVmax ≥10. Results: A total of 81 patients with R/R NHL were evaluated. Based on our definition, 40 (49%) patients would have been eligible for bridging RT, including 38 patients who met high-risk criteria: 31 with ≥1 EN site, 19 had ≥1 lesion with SUVmax ≥10, 16 with bulky disease, and 3 with elevated LDH. At 3 months after CART, ORRs in high-risk patients with <5 lesions, ≥5 lesions, and no lesions on pre-apheresis studies were 76% (CR 69%, PR 7%), 70% (CR 60%, PR 10%), and 80% (CR 80%), respectively. Conclusion: Approximately 47% (38/81) of patients were classified as at high risk of relapse after CART with disease encompassable in a standard radiation plan and eligible for bridging RT studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. 615 The impact of gender including female menopausal status on the safety and efficacy of immune checkpoint inhibitors

Author

Ari, Shaked Lev, primary, Zaemes, Jacob, additional, Ozisik, Deniz, additional, Zemel, Rachel A, additional, Tan, Ming, additional, Pascual, Lauren, additional, Sinclaire, Brittany, additional, Alaoui, Adil, additional, DellaPia, Alexandra, additional, Pecora, Andrew, additional, Atkins, Michael B, additional, Ip, Andrew, additional, and Shah, Neil J, additional

Published
2023
Full Text
View/download PDF

5. 1418 Treatment-free survival in patients with advanced melanoma and non-small cell lung cancer receiving immune checkpoint inhibitors: real-world outcomes over a 3-year timespan

Author

Zaemes, Jacob, primary, Ari, Shaked Lev, additional, Pascual, Lauren, additional, Jegede, Opeyemi A, additional, Arias-Orozco, Natali, additional, Sinclaire, Brittany, additional, DellaPia, Alexandra, additional, Zemel, Rachel A, additional, Zhang, Yili, additional, Gupta, Samir, additional, Alaoui, Adil, additional, Ip, Andrew, additional, Atkins, Michael B, additional, Regan, Meredith, additional, and Shah, Neil J, additional

Published
2023
Full Text
View/download PDF

6. Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.

Author

Ip, Andrew, Petrillo, Alessandra, Pia, Alexandra Della, Lee, Geeny G., Gill, Sarvarinder, Varughese, Tony, Zenreich, Joshua, Gutierrez, Martin, Zhang, Jiayu, Ahn, Jaeil, Bharani, Vishnu, Nejad, Ava S., Pascual, Lauren, Feldman, Tatyana A., Leslie, Lori A., and Goy, Andre H.

Subjects
LENALIDOMIDE, RITUXIMAB, NON-Hodgkin's lymphoma, EXANTHEMA
Abstract

Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that frequently becomes chemoresistant over time. The distinct mechanisms of ibrutinib and lenalidomide provided a judicious rationale to explore the combination with anti-CD20 immunotherapy. In this phase 1b study (NCT02446236), patients (n=25) with relapsed/refractory MCL received rituximab with escalating doses of lenalidomide (days 1–21) and ibrutinib 560mg (days 1–28) of 28-day cycles. The MTD for lenalidomide was 20mg; most common grade ≥3 adverse events were skin rashes (32%) and neutropenic fever (24%). The best ORR was 88%, CR rate was 83%, and median duration of response (DOR) was 36.92months (95% CI 33.77, 51.37). Responses were seen even in refractory patients or with high-risk features (e.g. blastoid variant, TP53 mutation, Ki-67>30%). R2I was safe and tolerable in patients with R/R MCL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

7. The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real‐world, multicenter, retrospective study

Author

Lev‐Ari, Shaked, primary, Serzan, Michael, additional, Wu, Tianmin, additional, Ip, Andrew, additional, Pascual, Lauren, additional, Sinclaire, Brittany, additional, Adams, Shari, additional, Marafelias, Michael, additional, Ayyagari, Lakshmi, additional, Gill, Sarvarinder K., additional, Ma, Barbara, additional, Zaemes, Jacob P., additional, Della Pia, Alexandra, additional, Alaoui, Adil, additional, Madhavan, Subha, additional, Belouali, Anas, additional, Pecora, Andrew, additional, Ahn, Jaeil, additional, Atkins, Michael B., additional, and Shah, Neil J., additional

Published
2023
Full Text
View/download PDF

8. Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study

Author

Mathema, Barun, primary, Chen, Liang, additional, Chow, Kar Fai, additional, Zhao, Yanan, additional, Zody, Michael C., additional, Mediavilla, Jose R., additional, Cunningham, Marcus H., additional, Composto, Kaelea, additional, Lee, Annie, additional, Oschwald, Dayna M., additional, Germer, Soren, additional, Fennessey, Samantha, additional, Patel, Kishan, additional, Wilson, David, additional, Cassell, Ann, additional, Pascual, Lauren, additional, Ip, Andrew, additional, Corvelo, André, additional, Dar, Sophia, additional, Kramer, Yael, additional, Maniatis, Tom, additional, Perlin, David S., additional, and Kreiswirth, Barry N., additional

Published
2021
Full Text
View/download PDF

9. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia

Author

Mato, Anthony R., Foon, Kenneth A., Feldman, Tatyana, Schuster, Stephen J., Svoboda, Jakub, Chow, Kar Fai, Valentinetti, Marisa, Mrkulic, Mary, Azzollini, Kelly, Gadaleta, Gabriella, Bhattacharyya, Pritish K., Zenreich, Joshua, Pascual, Lauren-Nicole, Yannotti, Kara, Kdiry, Sabrina, Howlett, Christina, Strelec, Lauren, Porter, David, Bejot, Coleen, and Goy, André

Published
2015
Full Text
View/download PDF

10. Post-vaccination SARS-COV-2 among healthcare workers in New Jersey: a genomic epidemiological study

Author

Mathema, Barun, primary, Chen, Liang, additional, Chow, Kar Fai, additional, Zhao, Yanan, additional, Zody, Michael C, additional, Mediavilla, Jose R, additional, Cunningham, Marcus H, additional, Composto, Kaelea, additional, Lee, Annie, additional, Oschwald, Dayna M, additional, Germer, Soren, additional, Fennessey, Samantha, additional, Patel, Kishan, additional, Wilson, David, additional, Cassell, Ann, additional, Pascual, Lauren, additional, Ip, Andrew, additional, Corvelo, André, additional, Dar, Sophia, additional, Kramer, Yael, additional, Maniatis, Tom, additional, Perlin, David S, additional, and Kreiswirth, Barry N, additional

Published
2021
Full Text
View/download PDF

11. 371 HISPANIC IBD PATIENTS WITH HLA-DQA1*05 HAVE HIGHER RATES OF ANTI-TNF IMMUNOGENICITY COMPARED TO NON-CARRIERS

Author

Ioannou, Stephanie, primary, Beecham, Ashley Harris, additional, Gomez, Lissette, additional, Dauer, Ryan M., additional, Khakoo, Nidah S., additional, Pascual, Lauren, additional, Quintero, Maria, additional, Mills, Grechen, additional, Lopez, Joanna, additional, Leavitt, James S., additional, Solis, Norma I., additional, Deshpande, Amar R., additional, Kerman, David H., additional, Abreu, Maria T., additional, McCauley, Jacob L., additional, and Damas, Oriana M., additional

Published
2021
Full Text
View/download PDF

22. A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR2 Regimen

Author

Mato, Anthony R., primary, Foon, Kenneth A., additional, Feldman, Tatyana, additional, Schuster, Stephen J., additional, Svoboda, Jakub, additional, Chow, Kar Fai, additional, Valentinetti, Marisa, additional, Morin, Mary, additional, Azzollini, Kelly, additional, Magarelli, Gabriella, additional, Bhattacharyya, Pritish K., additional, Zenreich, Joshua, additional, Howlett, Christina, additional, Pascual, Lauren-Nicole, additional, Yanotti, Kara, additional, Kdiry, Sabrina, additional, Porter, David, additional, and Goy, Andre, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results